<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01219413</url>
  </required_header>
  <id_info>
    <org_study_id>ST-4/Aliskiren/01</org_study_id>
    <nct_id>NCT01219413</nct_id>
  </id_info>
  <brief_title>Influence of Aliskiren on Proteinuria</brief_title>
  <acronym>ALIPRES</acronym>
  <official_title>The Effect of Aliskiren on Proteinuria in Chronic Nondiabetic Kidney Disease: a Double Blind Cross-over Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Gdansk</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Gdansk</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the proteinuria lowering efficacy as well as tolerability and safety of the renin
      inhibitor aliskiren compared with that of placebo and angiotensin converting enzyme inhibitor
      perindopril in patients with non-diabetic chronic renal disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Proteinuria is a major risk factor for progression to end-stage renal disease in both
      diabetic and nondiabetic nephropathies. Angiotensin II and aldosterone are the key players in
      the development of renal failure, either directly by promoting tissue fibrosis or indirectly
      through their action on glomerular hemodynamic and proteinuria. Therefore, pharmacological
      inhibition of the renin-angiotensin-aldosterone system (RAAS) may have a beneficial impact on
      proteinuria and chronic kidney diseases progression. Recently, renin inhibitors, a new class
      of drugs that selectively inhibits angiotensin II formation at the first step of the RAAS
      cascade has been introduced to clinical practice. Aliskiren is the first orally bioavailable
      direct renin inhibitor approved for the treatment of hypertension. Blood pressure
      (BP)-lowering effect of aliskiren is associated with a decreased generation of angiotensin I,
      as it blocks its generation from angiotensinogen, by inhibiting the active enzymatic site of
      renin. The investigators plan this study to evaluate the short-term effects of treatment with
      aliskiren to those of placebo and ACEI perindopril on proteinuria.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Investigate the antiproteinuric effect of adding aldosterone antagonist, spironolactone to the combination therapy with angiotensin converting enzyme inhibitor and AT-1 receptor blocker in maximal recommended doses. reduction of proteinuria</measure>
    <time_frame>march 2014 - april 2014</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>reduction of blood pressure</measure>
    <time_frame>march 2013 - april 2014</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <condition>Proteinuria</condition>
  <condition>Blood Pressure</condition>
  <arm_group>
    <arm_group_label>aliskiren, placebo, perindopril</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>perindopril, placebo, aliskiren</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aliskiren, Perindopril</intervention_name>
    <description>Rasilez 300 mg Prestarium 10 mg</description>
    <arm_group_label>aliskiren, placebo, perindopril</arm_group_label>
    <arm_group_label>perindopril, placebo, aliskiren</arm_group_label>
    <other_name>Rasilez 300 mg</other_name>
    <other_name>Prestarium 10 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18-65 years

          -  chronic non-diabetic proteinuric nephropathy

          -  creatinine clearance above 30 ml/min

          -  stable proteinuria above 500 mg/ 24 hours

          -  blood pressure above 125/75 mmHg and below 150/95 mmHg

          -  no steroids or other immunosuppressive treatment for a minimum of six months before
             the study

        Exclusion Criteria:

          -  unstable coronary heart disease

          -  decompensated congestive heart failure in the previous 6 months

          -  episode of malignant hypertension or stroke in the history

          -  diabetes

          -  creatinine clearance below 30 ml/min
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical University of Gdansk</name>
      <address>
        <city>Gdansk</city>
        <state>Pomorskie</state>
        <zip>80-211</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2010</study_first_submitted>
  <study_first_submitted_qc>October 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2010</study_first_posted>
  <last_update_submitted>September 23, 2015</last_update_submitted>
  <last_update_submitted_qc>September 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Gdansk</investigator_affiliation>
    <investigator_full_name>Leszek Tylicki</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>aliskiren</keyword>
  <keyword>renin inhibitor</keyword>
  <keyword>proteinuria</keyword>
  <keyword>chronic kidney diseases</keyword>
  <keyword>ACE inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Proteinuria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Perindopril</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

